Today's News: Middle East
SEE OTHER BRANDS

Following the news from the Middle East

Today's News: Middle East: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.

Press releases published on July 10, 2025

Byzanlink Selects Hedera to Advance Tokenized Financial Infrastructure for Institutional Markets

Byzanlink Selects Hedera to Advance Tokenized Financial Infrastructure for Institutional Markets

DUBAI, United Arab Emirates, July 10, 2025 (GLOBE NEWSWIRE) -- Byzanlink, a next-generation tokenization platform bridging traditional and decentralized finance, today announced a strategic partnership with the Hedera Foundation. In the first phase of the …

Medical Supplierz Announces Strategic Partnerships with Leading Healthcare Brands

Medical Supplierz Announces Strategic Partnerships with Leading Healthcare Brands

KUWAIT, KUWAIT, July 10, 2025 /⁨EINPresswire.com⁩/ -- Medical Supplierz, a digital B2B marketplace for medical equipment and supplies, has announced new partnerships with a select group of leading healthcare brands. These collaborations aim to enhance the …

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being …

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …

Maxus Mining Announces 2025 Exploration Program at its Penny Copper Project

Maxus Mining Announces 2025 Exploration Program at its Penny Copper Project

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to provide a summary of the 2025 exploration program (the “Program”) planned on its Penny Copper Project (the “ …

Aventis Energy Announces Partnership with KorrAI Technologies

Aventis Energy Announces Partnership with KorrAI Technologies

Highlights: The Company will leverage KorrAI’s revolutionary systems across the Project with aim to be more efficient in the potential discovery of mineralized outcrops. The cost-efficient technology integrates artificial intelligence, machine learning, …

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the …

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos …

Gauzy Ltd. Announces It Has No Plans to Raise Equity Under the Shelf Registration Currently and in the Foreseeable Future

Gauzy Ltd. Announces It Has No Plans to Raise Equity Under the Shelf Registration Currently and in the Foreseeable Future

Form F-3 recently filed as standard corporate governance procedure following shelf registration eligibility $35 million credit line is currently available under existing facility as previously disclosed TEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- …

Ero Copper Intercepts 105 Meters at 1.54% CuEq¹ at Furnas Copper-Gold Project – Successfully Completes Phase 1 Drill Program

Ero Copper Intercepts 105 Meters at 1.54% CuEq¹ at Furnas Copper-Gold Project – Successfully Completes Phase 1 Drill Program

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) ("Ero" or the “Company”) is pleased to announce the completion of its Phase 1 drill program at the Furnas Copper-Gold Project ("Furnas" or the "Project"), …

NexGold Infill Drilling Continues to Intersect High-Grade Gold Mineralization at the Goldboro Gold Project, Including 77.30 g/t over 1.25 metres and 19.32 g/t gold over 3.50 metres

NexGold Infill Drilling Continues to Intersect High-Grade Gold Mineralization at the Goldboro Gold Project, Including 77.30 g/t over 1.25 metres and 19.32 g/t gold over 3.50 metres

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to provide additional drill results from a recently-completed 26,854-metre diamond drill program initially announced on …

Pasinex Announces Closing of Shares for Debt Settlement

Pasinex Announces Closing of Shares for Debt Settlement

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE) (FSE: PNX) ("Pasinex" or the "Company") today announced that it has issued 28,766,306 common shares to certain of its creditors (the “Settlement Shares”) in exchange for …

Kiniero Grade Control Drilling Continues To Return High-Grade Gold Results

Kiniero Grade Control Drilling Continues To Return High-Grade Gold Results

QUEBEC CITY, July 10, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to report results from the Mansounia grade control …

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as …

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced …

Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

 - Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and …

Bitcoin Solaris Price Rollback Ignites Market Momentum Ahead of Major Exchange Launch

Bitcoin Solaris Price Rollback Ignites Market Momentum Ahead of Major Exchange Launch

TALLINN, Estonia, July 10, 2025 (GLOBE NEWSWIRE) -- Crypto winters come and go, but few events wake the market up like a perfectly timed price rollback. And Bitcoin Solaris just pulled off a surprise move that has investors scrambling. With major exchange …

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)- …

Bessor Announces Closing of Private Placement and Termination of Easter Project Option

Bessor Announces Closing of Private Placement and Termination of Easter Project Option

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, BC, July 09, 2025 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) is pleased to announce that it has completed …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service